On August 12, Vision Medicals, a precision medicine company in the field of infection, completed a Series B financing round worth 200 million yuan. The round was led by CDH Investments, with participation from CICC Capital as well as the company’s Series A investors Volcanics Venture, and CASH Capital.
Proceeds from this round of financing will be primarily used for product research and development and upgrading, the construction of the national clinical inspection network, medical device product registration, the construction of industrialization bases, and the strengthening of medical brand marketing and clinical services and other strategic directions.
Vision Medicals is a developer of a genetic technology and precision medicine designed to serve in medical diagnostic industry.
The company focuses on the research and development of a global leading detection technology platform and develops core technologies, genetic editing technology (CRISPR) and sequencing (NGS) platform, to provide medical diagnostics and clinical detection service, enabling clients to receive precise medical diagnosis in an efficient way.
Vision Medicals has built more than 5,000 square meters of medical testing laboratories and R&D centers in Beijing, Nanjing, Shanghai and Guangzhou, as well as GMP production bases for in-vitro diagnostic equipment and reagents.